Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Covalently crosslinked organophosphorous derivatives-chitosan hydrogel as a drug delivery system for oral administration of camptothecin.

Martínez-Martínez M, Rodríguez-Berna G, Bermejo M, Gonzalez-Alvarez I, Gonzalez-Alvarez M, Merino V.

Eur J Pharm Biopharm. 2019 Mar;136:174-183. doi: 10.1016/j.ejpb.2019.01.009. Epub 2019 Jan 14.

PMID:
30654016
2.

Ion-pair approach coupled with nanoparticle formation to increase bioavailability of a low permeability charged drug.

Lozoya-Agullo I, Planelles M, Merino-Sanjuán M, Bermejo M, Sarmento B, González-Álvarez I, González-Álvarez M.

Int J Pharm. 2019 Feb 25;557:36-42. doi: 10.1016/j.ijpharm.2018.12.038. Epub 2018 Dec 20.

PMID:
30578978
3.

Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 2: Fed State.

Paixão P, Bermejo M, Hens B, Tsume Y, Dickens J, Shedden K, Salehi N, Koenigsknecht MJ, Baker JR, Hasler WL, Lionberger R, Fan J, Wysocki J, Wen B, Lee A, Frances A, Amidon GE, Yu A, Benninghoff G, Löbenberg R, Talattof A, Sun D, Amidon GL.

Mol Pharm. 2018 Nov 12. doi: 10.1021/acs.molpharmaceut.8b00736. [Epub ahead of print]

PMID:
30417648
4.

Long-Circulating Hyaluronan-Based Nanohydrogels as Carriers of Hydrophobic Drugs.

Di Meo C, Martínez-Martínez M, Coviello T, Bermejo M, Merino V, Gonzalez-Alvarez I, Gonzalez-Alvarez M, Matricardi P.

Pharmaceutics. 2018 Nov 3;10(4). pii: E213. doi: 10.3390/pharmaceutics10040213.

5.

Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 1: Fasted State Conditions.

Bermejo M, Paixão P, Hens B, Tsume Y, Koenigsknecht MJ, Baker JR, Hasler WL, Lionberger R, Fan J, Dickens J, Shedden K, Wen B, Wysocki J, Löbenberg R, Lee A, Frances A, Amidon GE, Yu A, Salehi N, Talattof A, Benninghoff G, Sun D, Kuminek G, Cavanagh KL, Rodríguez-Hornedo N, Amidon GL.

Mol Pharm. 2018 Nov 12. doi: 10.1021/acs.molpharmaceut.8b00515. [Epub ahead of print]

PMID:
30372084
6.

Mass Transport Analysis of the Enhanced Buffer Capacity of the Bicarbonate-CO2 Buffer in a Phase-Heterogenous System: Physiological and Pharmaceutical Significance.

Al-Gousous J, Sun KX, McNamara DP, Hens B, Salehi N, Langguth P, Bermejo M, Amidon GE, Amidon GL.

Mol Pharm. 2018 Nov 5;15(11):5291-5301. doi: 10.1021/acs.molpharmaceut.8b00783. Epub 2018 Oct 26.

PMID:
30362350
7.

Determination of intestinal permeability using in situ perfusion model in rats: Challenges and advantages to BCS classification applied to digoxin.

Caldeira TG, Ruiz-Picazo A, Lozoya-Agullo I, Saúde-Guimarães DA, González-Álvarez M, de Souza J, González-Álvarez I, Bermejo M.

Int J Pharm. 2018 Nov 15;551(1-2):148-157. doi: 10.1016/j.ijpharm.2018.09.022. Epub 2018 Sep 13.

PMID:
30218825
8.

In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance.

Tsume Y, Patel S, Fotaki N, Bergstrӧm C, Amidon GL, Brasseur JG, Mudie DM, Sun D, Bermejo M, Gao P, Zhu W, Sperry DC, Vertzoni M, Parrott N, Lionberger R, Kambayashi A, Hermans A, Lu X, Amidon GE.

AAPS J. 2018 Sep 6;20(6):100. doi: 10.1208/s12248-018-0260-3. No abstract available.

PMID:
30191341
9.

Preclinical models for colonic absorption, application to controlled release formulation development.

Lozoya-Agullo I, González-Álvarez I, Merino-Sanjuán M, Bermejo M, González-Álvarez M.

Eur J Pharm Biopharm. 2018 Sep;130:247-259. doi: 10.1016/j.ejpb.2018.07.008. Epub 2018 Jul 6. Review.

PMID:
30064699
10.

Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded '21st Century BA/BE' project.

Hens B, Sinko PD, Job N, Dean M, Al-Gousous J, Salehi N, Ziff RM, Tsume Y, Bermejo M, Paixão P, Brasseur JG, Yu A, Talattof A, Benninghoff G, Langguth P, Lennernäs H, Hasler WL, Marciani L, Dickens J, Shedden K, Sun D, Amidon GE, Amidon GL.

Int J Pharm. 2018 Sep 5;548(1):120-127. doi: 10.1016/j.ijpharm.2018.06.050. Epub 2018 Jun 23. Review.

PMID:
29944899
11.

Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach.

Paixão P, Bermejo M, Hens B, Tsume Y, Dickens J, Shedden K, Salehi N, Koenigsknecht MJ, Baker JR, Hasler WL, Lionberger R, Fan J, Wysocki J, Wen B, Lee A, Frances A, Amidon GE, Yu A, Benninghoff G, Löbenberg R, Talattof A, Sun D, Amidon GL.

Eur J Pharm Biopharm. 2018 Aug;129:162-174. doi: 10.1016/j.ejpb.2018.05.033. Epub 2018 May 29.

PMID:
29857136
12.

Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system.

Del Moral Sanchez JM, Gonzalez-Alvarez I, Cerda-Revert A, Gonzalez-Alvarez M, Navarro-Ruiz A, Amidon GL, Bermejo M.

Br J Clin Pharmacol. 2018 Oct;84(10):2231-2241. doi: 10.1111/bcp.13650. Epub 2018 Jul 17.

PMID:
29846973
13.

In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC.

Ruiz Picazo A, Martinez-Martinez MT, Colón-Useche S, Iriarte R, Sánchez-Dengra B, González-Álvarez M, García-Arieta A, González-Álvarez I, Bermejo M.

Mol Pharm. 2018 Jun 4;15(6):2307-2315. doi: 10.1021/acs.molpharmaceut.8b00153. Epub 2018 May 17.

PMID:
29746133
14.

Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model.

Hens B, Talattof A, Paixão P, Bermejo M, Tsume Y, Löbenberg R, Amidon GL.

AAPS J. 2018 Mar 29;20(3):57. doi: 10.1208/s12248-018-0217-6.

PMID:
29600330
15.

Ionic Hydrogel Based on Chitosan Cross-Linked with 6-Phosphogluconic Trisodium Salt as a Drug Delivery System.

Martínez-Martínez M, Rodríguez-Berna G, Gonzalez-Alvarez I, Hernández MJ, Corma A, Bermejo M, Merino V, Gonzalez-Alvarez M.

Biomacromolecules. 2018 Apr 9;19(4):1294-1304. doi: 10.1021/acs.biomac.8b00108. Epub 2018 Mar 22.

PMID:
29537830
16.

Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter.

Mangas-Sanjuan V, Navarro-Fontestad C, García-Arieta A, Trocóniz IF, Bermejo M.

Eur J Pharm Sci. 2018 May 30;117:193-203. doi: 10.1016/j.ejps.2018.02.014. Epub 2018 Feb 13.

PMID:
29452210
17.

Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): An in vitro-in silico-in vivo approach.

Hens B, Bermejo M, Tsume Y, Gonzalez-Alvarez I, Ruan H, Matsui K, Amidon GE, Cavanagh KL, Kuminek G, Benninghoff G, Fan J, Rodríguez-Hornedo N, Amidon GL.

Eur J Pharm Sci. 2018 Mar 30;115:258-269. doi: 10.1016/j.ejps.2018.01.039.

PMID:
29378253
18.

Closed-Loop Doluisio (Colon, Small Intestine) and Single-Pass Intestinal Perfusion (Colon, Jejunum) in Rat-Biophysical Model and Predictions Based on Caco-2.

Lozoya-Agullo I, Gonzalez-Alvarez I, Zur M, Fine-Shamir N, Cohen Y, Markovic M, Garrigues TM, Dahan A, Gonzalez-Alvarez M, Merino-Sanjuán M, Bermejo M, Avdeef A.

Pharm Res. 2017 Dec 29;35(1):2. doi: 10.1007/s11095-017-2331-z.

PMID:
29288412
19.

PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen.

Lozoya-Agullo I, Araújo F, González-Álvarez I, Merino-Sanjuán M, González-Álvarez M, Bermejo M, Sarmento B.

Eur J Pharm Sci. 2018 Mar 30;115:119-125. doi: 10.1016/j.ejps.2017.12.009. Epub 2017 Dec 14.

PMID:
29248559
20.

Gated Mesoporous Silica Nanocarriers for a "Two-Step" Targeted System to Colonic Tissue.

González-Alvarez M, Coll C, Gonzalez-Alvarez I, Giménez C, Aznar E, Martínez-Bisbal MC, Lozoya-Agulló I, Bermejo M, Martínez-Máñez R, Sancenón F.

Mol Pharm. 2017 Dec 4;14(12):4442-4453. doi: 10.1021/acs.molpharmaceut.7b00565. Epub 2017 Nov 9.

PMID:
29064714

Supplemental Content

Loading ...
Support Center